» Articles » PMID: 25114486

Two-year Prospective Case-controlled Study of a Case Management Program for Community-dwelling Individuals with Schizophrenia

Overview
Specialty Psychiatry
Date 2014 Aug 13
PMID 25114486
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A community-based rehabilitation program is an essential element of the comprehensive treatment of individuals with schizophrenia.

Objective: Assess the long-term effects of a community-based case management program for providing rehabilitations services to individuals with schizophrenia.

Methods: A total of 730 community-residing participants who met ICD-10 diagnostic criteriafor schizophrenia were enrolled, 380 in the case management group and 350 in the control group from two districts in Shanghai. Case management involved monthly training visits with patients and their co-resident family members that focused on encouraging medication adherence. Participants were assessed every three months for 24 months with the Camberwell Assessment of Need (CAN), Positive and Negative Syndrome Scale (PANSS), WHO-Disability Assessment Scale (WHO-DAS), and the Quality of Life Scale (QOLS). Level of discomfort due to side-effects was also assessed every three months. Individuals who discontinued their antipsychotic medication without physician approval for one month or longer at any time during follow-up were classified as 'self-determined medication discontinuation'.

Results: Compared to the treatment as usual group (i.e., follow-up management every 3 months), by the end of the two-year follow-up those who participated in the case management program had significantly lower rates of medication discontinuation, significantly less severe negative symptoms, lower relapse rates and lower rehospitalization rates. Other factors that had an independent effect on discontinuation of medication included educational level (those with more education had higher discontinuation rates), lack of family supervision of medication, higher dosages of medication, and greater medication-related discomfort.

Conclusions: Case management is a feasible and effective long-term method for improving the rehabilitation outcomes of community residents with schizophrenia. Our results highlight the need to involve family members in the management of patients' medication, to use the minimum effective dosage of medication, and to aggressively manage all side-effects.

Citing Articles

Barriers and Facilitators of Engaging Community Health Workers in Non-Communicable Disease (NCD) Prevention and Control in China: A Systematic Review (2006⁻2016).

Long H, Huang W, Zheng P, Li J, Tao S, Tang S Int J Environ Res Public Health. 2018; 15(11).

PMID: 30373205 PMC: 6266440. DOI: 10.3390/ijerph15112378.


Delivery of public health services by community health workers (CHWs) in primary health care settings in China: a systematic review (1996-2016).

Huang W, Long H, Li J, Tao S, Zheng P, Tang S Glob Health Res Policy. 2018; 3:18.

PMID: 29992191 PMC: 5989355. DOI: 10.1186/s41256-018-0072-0.


Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region.

Lo T, Warden M, He Y, Si T, Kalyanasundaram S, Thirunavukarasu M Asia Pac Psychiatry. 2016; 8(2):154-71.

PMID: 27062665 PMC: 4834614. DOI: 10.1111/appy.12234.

References
1.
Malakouti S, Nojomi M, Panaghi L, Chimeh N, Mottaghipour Y, Joghatai M . Case-management for patients with schizophrenia in Iran: a comparative study of the clinical outcomes of Mental Health Workers and Consumers' Family Members as case managers. Community Ment Health J. 2009; 45(6):447-52. DOI: 10.1007/s10597-009-9197-4. View

2.
Chang L, Lin Y, Chang H, Chen Y, Huang W, Liu C . Psychopathology, rehospitalization and quality of life among patients with schizophrenia under home care case management in Taiwan. J Formos Med Assoc. 2013; 112(4):208-15. DOI: 10.1016/j.jfma.2012.01.018. View

3.
Holloway F, Oliver N, Collins E, Carson J . Case management: A critical review of the outcome literature. Eur Psychiatry. 2009; 10(3):113-28. DOI: 10.1016/0767-399X(96)80101-5. View

4.
Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G . Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012; 379(9831):2063-71. DOI: 10.1016/S0140-6736(12)60239-6. View

5.
Vita A, Barlati S, Deste G, Corsini P, De Peri L, Sacchetti E . Factors related to different reasons for antipsychotic drug discontinuation in the treatment of schizophrenia: a naturalistic 18-month follow-up study. Psychiatry Res. 2012; 200(2-3):96-101. DOI: 10.1016/j.psychres.2012.07.006. View